Alan L Epstein

Alan L. Epstein, MD, PhD, is a Professor at the Keck School of Medicine, University of Southern California, with dual appointments in Pathology and Pharmacology & Pharmaceutical Sciences. He holds a bachelor's degree in Biology from Wesleyan University and MD/PhD from Stanford University. His research focuses on cancer immunotherapy, monoclonal antibodies, and tumor targeting. Notable contributions include the development of Lym-1 antibody for lymphoma treatment, TNT antibodies for cancer imaging/therapy, and fusion proteins for immunotherapy. He has authored over 150 papers and 25 patents, with recent work emphasizing CAR-T cells, brain tumor therapy, and immune checkpoint modulation. Epstein has advised biotechnology companies and presented extensively on cancer therapeutics.

Education:

• Bachelor's in Biology, Wesleyan University
• MD and PhD, Stanford University Medical Scientist Training Program

Research Interests: Epstein's work spans antibody engineering, immunotherapy strategies, and tumor microenvironment modulation. He investigates CAR-T cells, checkpoint inhibitors, and targeted drug delivery systems to combat solid and hematologic malignancies. His lab explores biomarkers like IL-13 in BIA-ALCL and hypoxia-driven tumor progression.

Articles Trends: Recent publications highlight advances in brain tumor penetration of therapies, immune priming via radiation, and exosome-based vaccines. His work bridges preclinical models (e.g., murine glioma) with clinical applications, emphasizing CAR-T cell tracking and antibody pharmacokinetics.

Labs/Teams: Epstein's lab collaborates on developing therapeutic antibodies, fusion proteins, and nanotechnology-based delivery systems. He leads efforts in translational research, translating discoveries into clinical trials for lymphomas, solid tumors, and BIA-ALCL.